- Key Takeaways
- Prior authorization for dermatology covers far more than biologics. In a 2020 American Academy of Dermatology survey, respondents reported PA requirements for clobetasol, tretinoin and 5-fluorouracil.Â
- Dermatology requests run on two tracks: the pharmacy benefit for most prescriptions and the medical benefit for procedures and in-office services. Sending a request down the wrong track is a common, avoidable delay.Â
- Isotretinoin needs both the payerâs authorization and enrollment in the FDAâs iPLEDGE REMS program.Â
- An approval only protects revenue when the claim matches it on codes, units, dates, provider and site of service.Â
- CMS-0057-F sets decision deadlines for non-drug requests at certain government-sponsored and marketplace plans. Drug requests stay outside it until CMS finalizes its separate proposal, CMS-0062-P.Â
In a 2020 national survey by the American Academy of Dermatology, respondents reported that about one in four dermatology patients needed a prior authorization. Dermatologists and their staff spent an average of 3.3 hours a day on that work.Â
The list of affected treatments is also wider than most people assume. The same survey found authorization requirements for clobetasol, tretinoin and 5-fluorouracil. These are long-established, relatively inexpensive topicals, not specialty drugs.Â
For practice managers and billing teams, the prior authorization challenges in dermatology are no longer occasional exceptions. It is a daily workflow, and it has a direct line to revenue. Â
What Is Prior Authorization for Dermatology?
Prior authorization for dermatology is a payerâs requirement to approve a dermatology medication, procedure or service before the practice provides it. If you need a refresher on the general process, our guide to prior authorization in medical billing covers the fundamentals.Â
What makes dermatology different is that requests run on two separate tracks:Â
 | Pharmacy benefit | Medical benefit |
Covers | Most topicals, oral drugs and self-injected biologics | Procedures, office-administered drugs, phototherapy |
Reviewed by | Pharmacy benefit manager, often with a specialty pharmacy | The health planâs medical review |
Dermatology examples | Tretinoin, isotretinoin, most self-injected biologics | Mohs surgery, phototherapy, complex excisions |
Each track has its own forms, reviewers and timelines. A request sent down the wrong one doesnât move. That is one of the most common delays in the specialty, and one of the easiest to prevent.
Which Dermatology Treatments Commonly Require Prior Authorization?
The dermatology treatments that most often need prior authorization are:Â
- BiologicsÂ
- Many prescription topicalsÂ
- IsotretinoinÂ
- Phototherapy and laser treatmentÂ
- Mohs surgery or complex excisionsÂ
Requirements still vary by plan, product and diagnosis, so the patientâs current policy is the final word.Â
- Biologics and targeted therapies for psoriasis, atopic dermatitis and hidradenitis suppurativa. Most come with step therapy rules that require a documented trial of lower-cost options first.Â
- Topical prescriptions, including generics. In the AAD survey, 76% of respondents reported PA requirements for tretinoin and 65% for clobetasol.Â
- Isotretinoin, which runs on two separate tracks. One is the payerâs prior authorization. The other is the FDA-required iPLEDGE REMS program, with its own registration for prescribers, pharmacies and patients. Clearing one does not clear the other. The FDA approved changes to iPLEDGE in February 2026 to ease some of that burden, with a 180-day implementation window.Â
- Phototherapy and laser treatment, where payers look closely at whether the service is medical or cosmetic.Â
- Mohs surgery and complex excisions, which some plans require authorization for, particularly in Medicare Advantage and Medicaid managed care.Â
- Neolytix ⢠Prior Authorization
Prior Authorization
Why Do Dermatology Prior Authorizations Get Delayed or Denied?
Most prior authorization challenges in dermatology trace back to five problems: incomplete step therapy history, severity that isnât documented the way the policy asks, the wrong benefit route, treatment that reads as cosmetic, and expired approvals.Â
- Incomplete step therapy historyÂ
- Severity that isnât documented the way the policy asksÂ
- The wrong benefit routeÂ
- Treatment that reads as cosmeticÂ
- Expired approvalsÂ
The administrative load is heavy across medicine. The AMAâs 2025 physician survey found practices complete an average of 40 prior authorizations per physician each week, using 13 hours of physician and staff time. Nearly a third of physicians said requests are often or always denied.Â
In the AAD survey, 45% of dermatology determinations took longer than a week and 17% took longer than two weeks. The underlying causes repeat:Â
- Step therapy history is incomplete. The chart says âfailed topicalsâ but doesnât list which ones, for how long, or why they stopped.Â
- Severity isnât documented the way the policy asks. Many biologic policies want specific measures, such as affected body surface area. A narrative description often isnât enough.Â
- The request goes to the wrong benefit.Â
- The treatment reads as cosmetic. This happens most with laser and some excisions, when the medical indication isnât explicit in the note.Â
- The approval has expired. Biologic approvals are time-limited, and renewals slip when nobody owns the date.Â
Not every denial is the final answer. A 2022 federal OIG review of Medicare Advantage found that 13% of denied prior authorization requests met Medicare coverage rules. Those services likely would have been approved under traditional Medicare.Â
How Do Delays Affect Patients and Staff?Â
Patients feel it first. In the 2020 AAD survey, respondents said 12% of prior authorizations ended with treatment delayed or abandoned, and 17% led to a less appropriate treatment.Â
Staff feel it too. Sixty percent of dermatologists reported interrupting patient visits to deal with authorizations. Across specialties, 94% of physicians in the AMAâs 2025 survey said prior authorization contributes to burnout.Â
Why Can an Approved Authorization Still Lead to a Denied Claim?
An approved authorization still leads to a denied claim when the claim doesnât match what the payer approved. The procedure codes, units, date range, provider and site of service all have to line up. When they donât, the claim can be denied even though an authorization exists. Common examples are CARC 197 (authorization absent) and CARC 15 (authorization number missing, invalid or not applicable to the billed service).Â
Dermatology creates more mismatches than most specialties:Â
- Procedures can expand during the visit, through additional lesions or extra Mohs stages.Â
- Treatment can run past the approved date span.Â
- Patients can move between in-office phototherapy and other settings.Â
A quick authorization-to-claim check before submission catches most of these. Our dermatology billing and coding guide covers the coding side in more detail.
How Can Dermatology Practices Reduce Prior Authorization Delays?
You canât control the payerâs decision. You can control how complete and how fast your side of the process is.Â
- Check the requirement early. Confirm whether authorization is needed, and on which benefit, at scheduling or prescribing, not after.Â
- Document for the policy during the visit. Record the diagnosis, severity measures, prior therapies with dates and outcomes, and any contraindications before the chart closes. Templates for your highest-volume drugs and procedures help clinicians capture this without slowing down, while clinical judgment stays with them.Â
- Submit through electronic prior authorization (ePA) where the payer supports it. Keep the confirmation. ePA speeds up transmission and status checks, but it wonât fix missing documentation or change a payerâs criteria.Â
- Give every request one owner. Shared inboxes are where requests go to age.Â
- Track renewal dates. Start biologic re-authorizations well before they lapse.Â
- Reconcile the approval against the claim before it goes out.Â
- Review the metrics below monthly and update templates based on what you find.Â
Which Prior Authorization Metrics Should Dermatology Practices Track?
Track each stage separately, so you can see whether delays happen inside the practice or at the payer.Â
Metric | What it shows |
Time to submission | How long requests sit in the practice before reaching the payer |
Time to decision | How long the payer takes once the request is complete |
First-pass approval rate | Whether documentation meets payer criteria the first time |
Denial reasons by payer and drug | Which policies keep tripping up requests |
Renewals completed before expiry | Whether ongoing therapy stays protected |
Authorization-related claim denials | Revenue lost after approval through mismatches or missing authorization numbers |
What Should You Do When a Dermatology Prior Authorization Is Denied?
Start with the denial reason. Medicare Advantage plans, Medicaid and CHIP programs, and federal marketplace plans now have to state a specific reason when they deny a non-drug prior authorization. That tells you whether to resubmit with missing documentation or file an appeal.Â
For clinical denials, a peer-to-peer review with the planâs medical reviewer is often the fastest route. For drug denials, the AADâs Prior Authorization Appeal Letter Tool gives members and their staff templated letters for more than 70 dermatology drugs.Â
Practices that track appeal outcomes by payer quickly learn which denials are worth fighting. For more on the denial categories involved, see our overview of the top denials in medical billing.Â
When Should a Dermatology Practice Outsource Prior Authorization?
Outsourcing makes sense when authorization volume is steady, renewals keep slipping, or staff are regularly pulled away from patients to chase payers.Â
An outside team can take on the administrative work:Â
- Checking requirementsÂ
- Assembling packets from the existing chartÂ
- Submission and status trackingÂ
- Renewals and appeal preparationÂ
- Matching approvals to claimsÂ
Diagnosis, prescribing, medical necessity, peer-to-peer reviews and final appeal decisions stay with your clinicians.Â
Before signing, confirm three things. The partner should sign a BAA, show you request status without extra phone calls, and take ownership of renewal dates.
What Do CMS Rules and Insurer Pledges Change for Dermatology?
CMS-0057-F applies to Medicare Advantage, Medicaid, CHIP and federal marketplace plans.Â
- Decision deadlines: 72 hours for expedited requests and seven calendar days for standard ones. Federal marketplace plans are excluded from these deadlines.Â
- Denial reasons: a specific reason is required for denials starting in 2026.Â
- Electronic PA: these payers must build prior authorization APIs starting in 2027.Â
The catch for dermatology is that the rule excludes drugs. A Mohs or phototherapy request under a Medicare Advantage plan falls within it. A biologic request does not.Â
In April 2026, CMS proposed CMS-0062-P to extend similar requirements to drugs, with many provisions starting October 1, 2027. It is still a proposal, and the details may change. Our CMS-0062 explainer covers whatâs proposed. Commercial plans outside these programs follow their own policies and any state law that applies.Â
In June 2025, roughly 60 health insurers also pledged to simplify and reduce prior authorization, with deadlines running through 2027. Physicians remain skeptical: only 33% in the AMAâs 2025 survey said the pledge would make a meaningful difference. Until changes show up in your own payer mix, plan around the rules you see today.
Conclusion
Prior authorization for dermatology now reaches well beyond biologics, into routine topicals, isotretinoin, phototherapy and Mohs surgery. Requests run on two separate tracks, pharmacy benefit and medical benefit. Sending a request down the wrong one is among the easiest delays to prevent.Â
Most prior authorization challenges in dermatology come from a short list of fixable problems:Â
- Incomplete step therapy historyÂ
- Severity that isnât documented to the payerâs policyÂ
- Treatment that reads as cosmeticÂ
- Renewals that lapse because no one owns the dateÂ
Getting the approval doesnât finish the job. The claim still has to match what was approved, down to the codes, units, dates, provider and site.Â
Practices that check requirements early, document for the policy during the visit and give every request a single owner tend to see faster decisions. Tracking each stage separately shows whether a delay sits inside the practice or with the payer. When a denial does come, the specific reason tells you whether to resubmit, request a peer-to-peer review or appeal.Â
The rules are shifting, but slowly. CMS-0057-F already covers non-drug requests at certain plans. Drug requests stay outside it until CMS finalizes CMS-0062-P, and the 2025 insurer pledge has yet to win over most physicians. Until those changes show up in your own payer mix, a tight internal process is the most reliable protection for patient access and practice revenue.Â
- Neolytix ⢠Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
Sources
- American Academy of Dermatology survey (2020), Dermatology Online Journal: https://escholarship.org/uc/item/990631n9Â
- AMA 2025 Prior Authorization Physician Survey: https://www.ama-assn.org/press-center/ama-press-releases/ama-survey-prior-authorization-reform-pledge-falls-short-physiciansÂ
- CMS-0057-F fact sheet: https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-fÂ
- CMS-0062-P fact sheet: https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-ruleÂ
- FDA iPLEDGE REMS: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-remsÂ
- HHS-OIG, OEI-09-18-00260 (2022): https://oig.hhs.gov/reports/all/2022/some-medicare-advantage-organization-denials-of-prior-authorization-requests-raise-concerns-about-beneficiary-access-to-medically-necessary-careÂ
- AAD Prior Authorization Appeal Letter Tool: https://www.aad.org/member/practice/drugs/prior-authorizationÂ
Frequently Asked Questions
Do dermatologists need prior authorization for biologics?
In most cases, yes. Commercial, Medicare Advantage and Medicaid plans commonly require it for biologics used in psoriasis, atopic dermatitis and hidradenitis suppurativa, usually alongside step therapy documentation. Approvals are typically time-limited, so plan for re-authorization.
Does isotretinoin require prior authorization?
Often, yes, depending on the plan. Isotretinoin also requires participation in the FDAâs iPLEDGE REMS program, which is a separate process from the payerâs prior authorization. Both have to be complete before the patient can fill the prescription.
Does Mohs surgery require prior authorization?
It depends on the plan. Some Medicare Advantage and Medicaid managed care plans require it, and many commercial plans do not. Verify before scheduling. Confirm afterward that the billed stages and codes match what was approved.
How long does prior authorization take for dermatology medications?
In the American Academy of Dermatologyâs 2020 survey, 45% of determinations took more than a week and 17% took more than two weeks. Federal decision deadlines under CMS-0057-F do not yet apply to drug requests.
Can a denied dermatology prior authorization be overturned?
Often, yes. A 2022 HHS Office of Inspector General review found that 13% of prior authorization requests denied by Medicare Advantage plans met Medicare coverage rules. Read the specific denial reason, fix missing documentation, then request a peer-to-peer review or file an appeal.Â
